Celsion Corporation (NASDAQ:CLSN) has recently announced the latest translational data from the OVATION study of the Phase 1b dose clinical trials that combined GEN-1, Company’s […]
Boston, MA 02/07/2013 (wallstreetpr) – Shares of Celsion Corporation (NASDAQ:CLSN) increased by 8.82 percent to close at $1.11 on Monday. The shares recorded an intraday […]
Boston, MA 06/13/2013 (wallstreetpr) – The share prices of Celsion Corporation (NASDAQ:CLSN) had declined by 11.32 percent to close at $1.41 per share for the end […]
Boston, MA 05/30/2013 (wallstreetpr) – The share prices of Celsion Corporation (NASDAQ:CLSN) had increased by 39.47 percent to close at $1.59 per share for the end […]
